In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
 Javid Moslehi
Speaker
Javid Moslehi
Javid Moslehi Javid Moslehi

Vanderbilt University Medical Center, Nashville (United States of America)

Speciality : Basic Science

Dr. Moslehi is an Associate Professor of Medicine at Vanderbilt School of Medicine where he also directs the Cardio-Oncology program. Dr. Moslehi also directs a basic research laboratory, with general focus on mechanisms of cardiovascular toxicities that occur as a result of targeted cancer therapies and immunotherapies. Dr. Moslehi graduated from Johns Hopkins University and University of Connecticut School of Medicine. After completing an internal medicine residency at Johns Hopkins Hospital and clinical cardiology fellowship at the Brigham and Women's Hospital and Harvard Medical School, he started a basic science post-doctoral fellowship at the Dana-Farber Cancer Institute. In 2009, he founded the Cardio-Oncology program at Brigham and Women's Hospital/Dana-Farber Cancer Institute and Harvard Medical School before recruitment to Vanderbilt in 2014.

5 presentations from this speaker

Cardiovascular side effects of anti-tumor drugs.

Event : ESC Congress 2019

  • Session : Cardio-Oncology: Novel mechanisms and clinical implications
  • Speaker : J Moslehi (Nashville,US)

Cardiovascular toxicity associated with immune checkpoint inhibitors.

Event : ESC Congress 2019

  • Session : Cardio-oncology: what every cardiologist should know about cardiovascular effects of cancer treatment
  • Speaker : J Moslehi (Nashville,US)

Challenges in the long-term follow-up of cardio-oncology patients.

Event : ESC Congress 2019

  • Session : Cardiovascular health in cancer patients and survivors
  • Speaker : J Moslehi (Nashville,US)

Immunotherapy associated cardiotoxicity: pathophysiology, detection and treatment strategies

Event : Heart Failure 2019

  • Session : Special issues in cardio-oncology
  • Speaker : J Moslehi (Nashville,US)

What can we learn from cardiotoxic anti-cancer drugs?

Event : Heart Failure 2018

  • Session : Where does cardiology meet oncology?
  • Speaker : J Moslehi (Nashville,US)

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are